A Pharmacokinetic Study Of SB-681323 In Subjects With Coronary Heart Disease Undergoing Percutaneous Intervention

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Study of SB-681323 (a novel p38 MAPkinase inhibitor) in subjects with documented coronary heart disease (CHD) undergoing elective percutaneous coronary intervention (PCI).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO IV-EPIC 38)

NCT06535568

Coronary Disease Heart Diseases Cardiovascular Diseases +22 more

RECRUITING NA

Prevention of Cardiovascular Events by Antiplatelet Agents After Acute Coronary Syndrome

NCT01952392

Acute Coronary Syndrome

COMPLETED

A Study to Evaluate BMS-986141 Added on to Aspirin or Ticagrelor or the Combination, on Thrombus Formation in a Thrombosis Chamber Model in Participants With Stable Coronary Artery Disease and Healthy Participants

NCT05093790

Coronary Artery Disease Healthy Participants

COMPLETED PHASE2

Study on Safety and Effectiveness of Three Doses of Argatroban as Anticoagulant in Percutaneous Coronary Intervention (PCI)

NCT00508924

Coronary Artery Disease Angina, Unstable

COMPLETED PHASE2

A Study of SRSD107 in Participants With Chronic Coronary and/or Peripheral Arterial Disease

NCT07318155

Coronary Artery Disease (CAD) Peripheral Arterial Disease

NOT_YET_RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronary Heart Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SB-681323

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Females must be of non-child-bearing potential.
* Female subjects must have a negative pregnancy test.
* Subjects scheduled to undergo elective single vessel PCI to be performed within the 6 weeks of diagnostic coronary angiography.
* Must be on stable dose of statin for = 6 weeks prior to screening, with statin tolerability and LDL \<130 mg/dL (3.4 mmol/L) at Screening visit.
* Must be capable of providing informed consent.
* Have an hsCRP concentration of \>2 mg/L, but \< 10 mg/L at screening.

Exclusion Criteria

* Women who are pregnant or breast feeding.
* Planned PCI with multi-vessel stenting.
* Planned PCI with additional revascularization procedures staged at different days during the study period.
* Planned PCI other than stenting (e.g., atherectomy, PTCA without stenting, etc).
* Planned PCI of any bypass graft.
* History of CABG surgery.
* Planned cardiac or major non-cardiac surgery within the study period.
* Disabling stroke in the past 6 months.
* History of chronic viral hepatitis or other chronic hepatic disorders.
* History of Gilbert's syndrome or elevated bilirubin concentrations at screening.
* History of increased liver function tests (ALT, AST) due to acute or chronic liver conditions, above the upper limit of normal at screening or in the past 6 months.
* Renal impairment with serum creatinine \>2.0 mg/dl (177umol/L) at Screening, or history of kidney transplant, or a history of contrast nephropathy.
* Current inadequately controlled hypertension (blood pressure \>160 mmHg systolic and/or \>100 mmHg diastolic) on a stable dose of antihypertensive medication.
* Current poorly controlled diabetes mellitus, defined as HbA1c \>10% at Screening.
* History of severe heart failure defined as NYHA class III or IV or those with known severe LV dysfunction (EF\<30%) regardless of symptomatic status.
* History of malignancy within the past 5 years, other than non-melanoma skin cancer.
* Current life-threatening condition other than vascular disease that may prevent a subject from completing the study.
* Alcohol or drug abuse within the past 6 months.

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No